The FDA’s Science Board subcommittee to help agency improve device branch

FDA Science Board subcommittee to help agency improve device branch

The FDA’s Science Board yesterday agreed to form a new subcommittee to help the agency examine 3 specified domains of regulatory science activities related to medical devices, assess progress made since 2007, and address the challenges posed by rapidly evolving science and technology.

These challenges include the scientific implications of the increasing globalization of product development and supply chains, the federal watchdog agency noted in background materials released ahead of the meeting.

The FDA specifically requested that the new subcommittee make its recommendations with the agency’s current staff and financial resources in mind, but also welcomed additional recommendations for steps the agency could take if new, additional resources for regulatory science are made available.

The new subcommittee will assess FDA’s progress since 2007, when "FDA Science and Mission at Risk: Report of the Subcommittee on Science and Technology" was released. That report found that "the demands on the FDA have soared … and the resources have not increased in proportion to the demands."

The previous subcommittee called for strategic leadership and support, including new resources; for strengthening science at FDA, with particular attention to emerging technologies; and for strengthening professional development, according to the agency.

The new subcommittee will provide feedback on how well the FDA’s "Strategic Plan for Regulatory Science" captures FDA’s cross-cutting scientific needs and whether modifications should be made to the plan. It will also recommend additional steps FDA could take to best position itself to meet emerging and future trends in science, technology and FDA-regulated products.

The subcommittee is also tasked with suggesting how the FDA can better collaborate with public and private sector entities, suggest strategies and frameworks for collaboration, and recommend potential new collaborations to advance the agency’s mission, the agency said.

And the new subcommittee will provide feedback on FDA’s activities in recent years to "foster an environment of scientific excellence" and make suggestions for what additional steps the agency could take to further support such a culture.

The safety bureau expects to provide the new subcommittee with a progress report that includes specific questions for input within a year, according to chief scientist Dr. Jesse Goodman.

Financial and strategic threats to FDA’s device branch

A draft report published ahead of the meeting, "Protecting the core of CDRH regulatory science in the face of financial and strategic threats," summarizes how FDA’s device branch, the Center for Devices & Radiological Health, can function most efficiently, but warns against cost-cutting.

"Loss in federal investment in regulatory science at CDRH will interfere with the regulatory approval of emerging technologies and in doing so cost lives," according to the report. "With the medical device industry setting a record pace in advancing life-saving technology, there is no more pressing need at the FDA than to fund fully a robust and successful CDRH regulatory science program."

The report details several threats to the success of the device branch, including the FDA’s ability to keep up on technological advances, a political environment that limits the resources available for scientific growth within the CDRH, and a limited science staff.

The report also makes several specific recommendations related to the CDRH’s mission and scope, the branch’s organization, and how to enhance advocacy, communication, collaboration and funding for the agency’s device branch.

The medical device center’s primary research mission should be to foster science and engineering with a clear link to regulatory challenges, the Science Board states.

"Every project, laboratory and division should be completely aligned to this mission that no other government agency has," according to the board.

Better public understanding of the CDRH’s critical role in conducting research is needed. This can be gained through heightened visibility, enhanced by research collaborations and educational efforts, the report concludes.

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply